• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 69Response to pharmacological treatment: findings of the network meta-analysis and of classical pair-wise comparisons versus placebo

DrugNetwork meta-analysis (results for 8 weeks)
Conditional response
Classical pair-wise meta-analysis – non-response
Pr of conditional response (95% CrI)Pr that drug is best in achieving response (in those who have not discontinued the drug due to side effects)HR versus placebo (95% CrI) – conditional responseRR versus placebo (95% CI) – non-response
Duloxetine0.651 (0.357, 0.919)0.3661.971 (1.549, 2.473)0.75 (0.62, 0.90)
Sertraline0.629 (0.329, 0.910)0.2771.859 (1.302, 2.591)0.70 (0.57, 0.86)
Venlafaxine XL0.616 (0.337, 0.892)0.1661.777 (1.482, 2.120)0.80 (0.71, 0.92)
Pregabalin0.590 (0.315, 0.872)0.0901.643 (1.349, 1.978)0.79 (0.73, 0.85)
Escitalopram0.579 (0.305, 0.870)0.0831.596 (1.237, 2.020)0.78 (0.63, 0.97)
Paroxetine0.519 (0.261, 0.822)0.0181.330 (1.059, 1.660)0.91 (0.73, 1.13)
Placebo0.428 (0.223, 0.684)0.000


Cover of Generalised Anxiety Disorder in Adults
Generalised Anxiety Disorder in Adults: Management in Primary, Secondary and Community Care.
NICE Clinical Guidelines, No. 113.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2011.
Copyright © 2011, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.